Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | GUSB | P08236 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151836 | 0.89 | GLA (0.78) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL9701605 | 0.88 | GLA (0.76) | GLAALDH1A1LMNATHRBTSHR | |
| Bamnidazole SCHEMBL635607 | 0.88 | GLA (1.00) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL5143254 | 0.88 | GLA (0.76) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL9702344 | 0.85 | GLA (0.73) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL3772284 | 0.85 | GLA (0.73) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL3777173 | 0.85 | GLA (0.73) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL9701202 | 0.84 | GLA (0.71) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL9701341 | 0.84 | GLA (0.71) | GLAALDH1A1LMNATHRBTSHR | |
| SCHEMBL11853645 | 0.84 | GLA (0.71) | GLAALDH1A1LMNATHRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317707-A1 | Oligomer-Nitroimidazole Anti-Infective Conjugates | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | US | claimed |
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | disclosed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | disclosed |
| CN-115785185-B | Bile acid-metronidazole conjugate and application thereof | 华南理工大学 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024120184-A1 | BILE ACID-METRONIDAZOLE CONJUGATE AND USE THEREOF | 华南理工大学 | 2024-06-13 | — | — | WO | disclosed |
| CN-115785185-A | Bile acid-metronidazole conjugate and application thereof | 华南理工大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-115175926-A | Activatable cytokine polypeptides and methods of use thereof | 狼人治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-113219045-B | Composite nano material, preparation method and application thereof | 山东农业大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-113219045-A | Composite nano material, preparation method and application thereof | 山东农业大学 | 2021-08-06 | — | — | CN | disclosed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | disclosed |
| US-20100048645-A1 | Solubilizing of metronidazole | Galderma Holding SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20090163568-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA S.A. (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | MARTON MILANKOVITS | 2009-05-14 | — | — | US | disclosed |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | MILANKOVITS MARTON | 2009-03-19 | — | — | US | disclosed |
| US-20080194664-A1 | Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea | GALDERMA S.A. (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080161375-A1 | Solubilizing of metronidazole | GALDERMA S.A. (CH) | 2008-07-03 | — | — | US | disclosed |
| US-20080103110-A1 | Compounds | DRUG DISCOVERY LABORATORY AS (NO) | 2008-05-01 | — | — | US | disclosed |
| US-20050208152-A1 | Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications | MILANKOVITS MARTON | 2005-09-22 | — | — | US | disclosed |
| WO-1992010502-A1 | HETEROCYCLIC CARBOXYLIC ESTERS, METHODS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF GASTRO-INTESTINAL MEDICINES | BROCADES PHARMA B.V. (NL) | 1992-06-25 | — | — | WO | disclosed |
| EP-0490450-A1 | Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines | YAMANOUCHI EUROPE B.V. (NL) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | GLA 4466/4885ALDH1A1 3471/4885LMNA 3271/4885 |
| US-20080103110-A1 | Compounds | ATIC, CDA, PAICS | GLA 2892/4885ALDH1A1 941/4885LMNA 2537/4885 |
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | GLA 4466/4885ALDH1A1 3471/4885LMNA 3271/4885 |
| US-20090124593-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their ExtraGenital Complications | SOD1, OAT, ELANE | GLA 67/4885ALDH1A1 1707/4885LMNA 1038/4885 |
| US-20090074839-A1 | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications | DHFR, FPGS, FOLR1 | GLA 947/4885ALDH1A1 4171/4885LMNA 4659/4885 |
| US-20100317707-A1 | Oligomer-Nitroimidazole Anti-Infective Conjugates | NOD2, NOD1, NEDD8 | GLA 4268/4885ALDH1A1 3411/4885LMNA 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.